Cadrenal Therapeutics discloses Form D for completed private placement

Cadrenal Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission disclosing a private securities offering. The filing marks a new notice with a date of first sale of June 30, 2026.¹

The total offering amount was $8,843,849, with the same amount reported as sold and $0 remaining to be sold.¹ The company noted that this total reflects gross proceeds assuming cash exercise of all warrants issued in the private placement.¹

The securities offered included an option, warrant, or other right to acquire another security, as well as a security to be acquired upon exercise of such a right.¹

H.C. Wainwright & Co., LLC, based in New York, was listed as a recipient of sales compensation.¹ The placement agent received a 7.0% cash fee of $210,000, a 1.0% management fee of $30,000, non-accountable expenses of $25,000, accountable expenses of $50,000, and warrants to purchase 62,4000 shares of common stock.¹ Total sales commissions were estimated at $315,000.¹

The filing indicated a total of one investor had already invested in the offering.¹ The offering was claimed under Rule 506(b) of Regulation D.¹

The Form D was signed by Quang X. Pham, Chairman of the Board and Chief Executive Officer, on July 15, 2026.¹ That date reflects the filing's signature date rather than the date securities were first sold.